ArticleAnnals of internal medicine2024
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
Article in Annals of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.Nature medicine · 2025Trial
- Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX-A narrative review.Annals of medicine · 2026Review
- Narrative Review of Novel Nicotine-Delivery Systems and Emerging Pharmaceuticals for Tobacco Cessation.Medicines (Basel, Switzerland) · 2026Review
- Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment.Communications medicine · 2026Article
- GLP-1 receptor agonists are associated with reduced nicotine dependence in hidradenitis suppurativa: A TriNetX new-user, active-comparator study.JAAD international · 2026Article
- Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study.Psychopharmacology · 2026Article
- Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.Journal of clinical medicine · 2026Review
- GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation.EClinicalMedicine · 2026Article
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.BMJ (Clinical research ed.) · 2026Article
- Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.Journal of clinical medicine · 2026Review
- Article
- Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.Frontiers in clinical diabetes and healthcare · 2026Article
- A Pharmacological Update and Safety Analysis of Medications for Smoking Cessation: Which Ones to Use?Current pharmaceutical design · 2026Review
- Peripheral nerve complications of weight loss associated with novel antihyperglycemic agents: a cohort study.Journal of neurology · 2025Article
- Glucagon-like peptide-1 medicines in neurological and psychiatric disorders.Cell reports. Medicine · 2025Review
- GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.Journal of the Endocrine Society · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundReports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).
objectiveTo examine the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD.
designEmulation target trial based on a nationwide population-based database of patient electronic health records.
settingUnited States, 1 December 2017 to 31 March 2023.
participantsSeven target trials were emulated among eligible patients with comorbid T2DM and TUD by comparing the new use of semaglutide versus 7 other antidiabetes medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other GLP-1RAs). MEASUREMENTS: The TUD-related health care measures (medical encounter for diagnosis of TUD, smoking cessation medication prescriptions, and smoking cessation counseling) that occurred within a 12-month follow-up were examined using Cox proportional hazards and Kaplan-Meier survival analyses.
resultsThe study compared 222 942 new users of antidiabetes medications including 5967 of semaglutide. Semaglutide was associated with a significantly lower risk for medical encounters for TUD diagnosis compared with other antidiabetes medications, and was strongest compared with insulins (hazard ratio [HR], 0.68 [95% CI, 0.63 to 0.74]) and weakest but statistically significant compared with other GLP-1RAs (HR, 0.88 [CI, 0.81 to 0.96]). Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling. Similar findings were observed in patients with and without a diagnosis of obesity. For most of the group comparisons, the differences occurred within 30 days of prescription initiation. LIMITATION: Documentation bias, residual confounding, missing data on current smoking behavior, body mass index, and medication adherence.
conclusionSemaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid T2DM and TUD compared with other antidiabetes medications including other GLP-1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide's potential for TUD treatment. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.